#2 Advanced Accelerator Application SA (ADR) (NASDAQ:AAAP)
– Shares Owned by Sio Capital (as of December 31): 291,877
– Value of Holding (as of December 31): $9.13 Million
Since its IPO in November, shares of the $1.29 billion radiopharmaceutical company are up by more than 36%. The company’s lead drug, Lutathera, treats midgut neuroendocrine tumors (NETs). The drug met its primary endpoint in Phase 3 trials and has also shown promising results in the Interim OS analysis. Moreover, Advanced Accelerator Application SA (ADR) (NASDAQ:AAAP) also received an extension on its Prescription Drug User Fee Act (PDUFA) date for its Priority Review of the Company’s New Drug Application (NDA) for Somakit-TATE, which is used in neuroendocrine tumor diagnosis. Among the funds we track, Phill Gross and Robert Atchinson‘s Adage Capital is the largest shareholder of Advanced Accelerator Application SA (ADR) (NASDAQ:AAAP) with about 1.23 million shares valued at $38.46 million.
#1 McKesson Corporation (NYSE:MCK)
– Shares Owned by Sio Capital (as of December 31): 56,000
– Value of Holding (as of December 31): $11.05 Million
Sio’s stake McKesson Corporation (NYSE:MCK) represents 4.89% of the fund’s equity portfolio. The stock price of the San Francisco-based drug distributor and provider of technology solutions has fallen by more than 32% over the last 52 weeks, despite gaining 11% during the fourth quarter. The company recently acquired two cancer-care companies, Biologics and Vantage Oncology for $1.2 billion. Moody’s sees the deal as credit positive and expects financial leverage to remain the same, while McKesson expands its reach in specialty services. Parsa’s Kiai‘s Steamboat CApital Partners purchased some 94,300 shares of McKesson Corporation (NYSE:MCK) during the fourth quarter.